Endoscopy 2022; 54(05): 503-508
DOI: 10.1055/a-1550-2503
Innovations and brief communications

Detection of soluble biomarkers of pancreatic cancer in endoscopic ultrasound-guided fine-needle aspiration samples

Régis Souche*
 1   Department of Digestive Surgery and Transplantation, Hôpital Saint Eloi, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France
 2   Tumor Microenvironment and Resistance-to-Treatment Laboratory, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier, France
 3   Institut régional du Cancer Montpellier (ICM), Parc Euromédecine, Montpellier, France
 4   Université de Montpellier, Montpellier, France
,
Guillaume Tosato*
 3   Institut régional du Cancer Montpellier (ICM), Parc Euromédecine, Montpellier, France
 4   Université de Montpellier, Montpellier, France
 5   Cancer Bioinformatics and Systems Biology, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France
 6   Centre Hospitalier Universitaire Lapeyronie, Montpellier, France
,
Benjamin Rivière
 7   Department of Pathology, Hôpital Saint Eloi, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France
,
Jean-Christophe Valats
 4   Université de Montpellier, Montpellier, France
 8   Department of Hepatogastroenterology, Hôpital Saint Eloi, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France
,
Antoine Debourdeau
 4   Université de Montpellier, Montpellier, France
 8   Department of Hepatogastroenterology, Hôpital Saint Eloi, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France
,
Nicolas Flori
 3   Institut régional du Cancer Montpellier (ICM), Parc Euromédecine, Montpellier, France
 9   Clinical Nutrition, Gastroenterology and Endoscopy, Univ Montpellier, Institut régional du Cancer Montpellier (ICM), Montpellier, France
,
Didier Pourquier
 2   Tumor Microenvironment and Resistance-to-Treatment Laboratory, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier, France
 3   Institut régional du Cancer Montpellier (ICM), Parc Euromédecine, Montpellier, France
10   Department of Pathology, Institut Régional du Cancer Montpellier (ICM), Montpellier, France
,
Jean-Michel Fabre
 1   Department of Digestive Surgery and Transplantation, Hôpital Saint Eloi, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France
 4   Université de Montpellier, Montpellier, France
,
Eric Assenat
 4   Université de Montpellier, Montpellier, France
11   Department of Medical Oncology, Hôpital Saint Eloi, Centre Hospitalier Universitaire, Université de Montpellier, Montpellier, France
,
Jacques Colinge****
 3   Institut régional du Cancer Montpellier (ICM), Parc Euromédecine, Montpellier, France
 4   Université de Montpellier, Montpellier, France
 5   Cancer Bioinformatics and Systems Biology, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France
,
Andrei Turtoi**
 2   Tumor Microenvironment and Resistance-to-Treatment Laboratory, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Montpellier, France
 3   Institut régional du Cancer Montpellier (ICM), Parc Euromédecine, Montpellier, France
 4   Université de Montpellier, Montpellier, France
› Author Affiliations
Supported by: Centre Hospitalier Régional Universitaire de Montpellier http://dx.doi.org/10.13039/501100005261

Trial Registration: ClinicalTrials.gov Registration number (trial ID): NCT03791073 Type of study: Retrospective, Multi-Center


Abstract

Background Biomarkers are urgently needed for pancreatic ductal adenocarcinoma (PDAC). Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is the cornerstone for diagnosing PDAC. We developed a method for discovery of PDAC biomarkers using the discarded EUS-FNA liquid.

Methods This retrospective study included 58 patients with suspected pancreatic lesions who underwent EUS-FNA. Protein extracts from EUS-FNA liquid were analyzed by mass spectrometry. Proteomic and clinical data were modeled by supervised statistical learning to identify protein markers and clinical variables that distinguish PDAC.

Results Statistical modeling revealed a protein signature for PDAC screening that achieved high sensitivity and specificity (0.92, 95 % confidence interval [CI] 0.79–0.98, and 0.85, 95 %CI 0.67–0.93, respectively). We also developed a protein signature score (PSS) to guide PDAC diagnosis. In combination with patient age, the PSS achieved 100 % certainty in correctly identifying PDAC patients > 54 years. In addition, 3 /4 inconclusive EUS-FNA biopsies were correctly identified using PSS.

Conclusions EUS-FNA-derived fluid is a rich source of PDAC proteins with biomarker potential. The PSS requires further validation and verification of the feasibility of measuring these proteins in patient sera.

* Co-first authors


** Co-last authors


Supplementary material



Publication History

Received: 28 December 2020

Accepted after revision: 14 June 2021

Publication Date:
26 August 2021 (online)

© 2021. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany